D.A. Davidson & Co’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

D.A. Davidson & Co’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,958	Closed	-$23K	–	1174
2017 Q4	$23K	Buy	+13,958	New	+$24K	﹤0.01%	1104
2017 Q3	–	Sell	-8,016	Closed	-$12K	–	2302
2017 Q2	$12K	Sell	8,016 -4,628	-37%	-$10.4K	﹤0.01%	1996
2017 Q1	$43K	Sell	12,644 -1,454	-10%	-$6.88K	﹤0.01%	1576
2016 Q4	$73K	Sell	14,098 -25,615	-65%	-$443K	﹤0.01%	1448
2016 Q3	$1M	Buy	39,713 +31,969	+413%	+$806K	0.02%	467
2016 Q2	$191K	Buy	7,744 +75	+1%	+$2.12K	0.01%	860
2016 Q1	$222K	Buy	+7,669	New	+$208K	0.01%	798
2015 Q4	–	Sell	-375	Closed	-$18K	–	2325
2015 Q3	$18K	Sell	375 -250	-40%	-$17.5K	﹤0.01%	1705
2015 Q2	$43K	Buy	625 +262	+72%	+$12.1K	﹤0.01%	1494
2015 Q1	$12K	Buy	+363	New	+$10.7K	﹤0.01%	1768

Other funds holding ANTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.A. Davidson & Co's ANTH Position: Q1 2018 in Review

D.A. Davidson & Co sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2018, closing a stake of 13,958 shares — an estimated $23K sold.

D.A. Davidson & Co first reported a position in ANTH in Q1 2015 and held it in 10 quarters. The position peaked at $1M in Q3 2016. 28 funds tracked by Wall St. Rank hold ANTH as of Q1 2018.

D.A. Davidson & Co reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
D.A. Davidson & Co sold 13,958 Anthera Pharmaceuticals, Inc. shares in Q1 2018, an estimated $23K.
D.A. Davidson & Co first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
D.A. Davidson & Co's Anthera Pharmaceuticals, Inc. position peaked at $1M in Q3 2016.
28 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2018.

Based on D.A. Davidson & Co's 13F filing for Q1 2018, filed 4 May 2018.